Business Wire

Incepto, the French Digital Health Specialist, is Raising €27 million to Support Its European Development

19.9.2022 10:00:00 EEST | Business Wire | Press release

Share

Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today. The financing round is led by LBO France's Venture - Digital Health team, with the participation of Wille Finance and the historical investors AXA Venture Partners, the Patient Autonome fund of Bpifrance and Karista. This financing marks a new stage for Incepto, which is launching its offer in four new countries in Europe (Germany, Spain, Italy and Portugal).

As part of Incepto’s development, four new subsidiaries are created in Germany, Spain, Italy and Portugal with the aim of anchoring its position as European leader in the sector and treat one million European patients per month by 2024.

From a French start-up to a European scale-up

Incepto is also announcing the signing of five new partnerships (IB Lab, Milvue, PAIRE, SmartSoft and Thirona) to expand its portfolio of medical imaging applications for emergency care, oncology, orthopaedics, rheumatology and pneumology.

By extending its geographical coverage and developing its portfolio of applications, Incepto is responding to major public health issues: reducing waiting times for examinations, mitigating the lack of specialists for certain serious diseases and supporting doctors' work in the face of the increasing amount of data to be analysed.

In light with the explosion of the AI market in Europe, Incepto has three strategic objectives:

Selecting and make available the most powerful AI solutions in medical imaging for each specialty, guaranteeing high quality standards;

Creating, with doctors new applications that meet real needs but that do not exist yet: ARVA and KEROS are thus the first products co-developed by Incepto for the diagnostic assistance of aortic aneurysms in CT scanners and for MRI of the knee;

Supporting the transformation of organisations and working methods by rethinking patient care with medical teams to exploit the full potential of artificial intelligence technologies.

About Incepto

Created in 2018, Incepto is the first European platform for artificial intelligence solutions applied to medical imaging. With a hundred clinics equipped with their AI solutions and already more than 100,000 patients monitored every month, Incepto's mission is twofold: to help doctors identify the most efficient solutions and put them at their service, while co-creating new applications with them, adapted to their specific needs. Incepto's ambition is to assist doctors on a daily basis in improving the accuracy of diagnoses, the treatment process and the quality of patient care.

https://incepto-medical.com/fr

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contact
Aude Vayre : 00 33 6 14 64 15 65 / aude.vayre@grayling.com
Anne Levasseur : 00 33 6 68 52 14 09 / anne.levasseur@citigatedewerogerson.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Only 7% of Companies Achieve Full Compliance as Global Expansion Increases Legal Complexity11.5.2026 16:00:00 EEST | Press release

As businesses accelerate their global expansion in 2026, compliance fails to keep pace. In fact, only 7% of organizations report full compliance across their global entities, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 350 general counsel (GCs) and senior legal professionals across Europe, North America, and Asia Pacific to examine how their teams navigate international expansion, regulatory pressure, and the increasing adoption of artificial intelligence (AI).¹ The findings appear in CSC’s latest report, General Counsel Barometer 2026: From Complexity to Control. Most organizations report partial compliance, with over half (53%) estimating they are 50–75% compliant, and a further 35% placing themselves between 76%–99%. This leaves just 7% of organizations reporting full compliance across all global entities. GCs also report low confidence in addressing ongoing demands amid global expansion. More than tw

IFF Opens Vanilla Innovation Center in Madagascar11.5.2026 15:15:00 EEST | Press release

IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health & bioscience—today announced the opening of its Vanilla Innovation Center in Madagascar, reinforcing vanilla as a strategic and priority tonality for IFF and strengthening its ability to innovate at origin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260508110162/en/ IFF's Vanilla Innovation Center in Madagascar “The opening of the center marks an important step in how we approach vanilla innovation,” said Adam Jańczuk, Ph.D., senior vice president, research, creation and design, Taste, IFF. “By strengthening our presence at origin, we connect science, creativity and sustainability more closely, responding to climate changes, safeguarding quality and creating value across the supply chain.” Located in Toamasina, Madagascar’s principal seaport, near vanilla growing areas and post‑harvest processing activities, the 650‑square‑meter center bring

ARIS Recognised as a Leader in Gartner ® Magic Quadrant™ for Process Intelligence Platforms, Believes This Reinforces Its Role in Enabling Enterprise AI at Scale11.5.2026 15:00:00 EEST | Press release

ARIS, the process context foundation platform for enterprise AI deployment, today announced its recognition as a Leader in the Gartner® Magic Quadrant™ for Process Intelligence Platforms. This is the fourth consecutive year that ARIS has been recognized as a Leader in the report and the company believes it underscores a continued commitment to innovation and growth as enterprises focus on turning AI ambition into measurable business outcomes. While technology has advanced rapidly, companies are struggling to operationalise AI across complex operating models. ARIS sees this recognition by Gartner as a reflection of its strength in delivering a single unified platform for process intelligence, providing the context layer on which G2000 organisations can successfully deploy and scale agentic AI. “AI is moving from experimentation to execution – but many enterprises are finding it difficult to scale,” said Guillaume Bacuvier, CEO of ARIS. “The reason is simple: AI lacks the context it need

Logistics Reply Named a Visionary in 2026 Gartner® Magic Quadrant™ for Warehouse Management Systems and Ranks #2 for Level 2 and #3 for Level 3 Operations Use Cases in Gartner® Critical Capabilities Report11.5.2026 15:00:00 EEST | Press release

Logistics Reply, the Reply Group company specializing in innovative solutions for supply chain execution, is proud to announce its recognition as a Visionary in the Gartner® Magic Quadrant™ for Warehouse Management Systems for the seventh consecutive year, as its global team of warehouse technology professionals continues to drive innovation that puts customers first. Additionally, Logistics Reply for its LEA Reply™ WMS is recognized in the 2026 Gartner® Critical Capabilities for Warehouse Management Systems report where it ranked #2 for Level 2 Warehouse Operations and #3 for Level 3 Warehouse Operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511344452/en/ We believe these important recognitions underscore Logistics Reply's commitment to delivering intelligent, flexible and scalable warehouse execution solutions for enterprise customers around the world. For us, our placement in the Visionaries Quadrant reflects

HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors11.5.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking authorization to expand the use of its Edison® Histotripsy System to include the destruction of kidney (renal) tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511268688/en/ HistoSonics Edison® Histotripsy System This milestone marks a significant step forward in the company’s mission to transform the treatment of solid tumors with a completely non-invasive technology that harnesses focused ultrasound to mechanically liquefy and destroy targeted tissue, reducing the risk of many complications and side effects associated with surgery, radiation, and other common therapies. “This submission is an important milestone in expanding histotripsy beyond the liver and into the kidney, an area where patients and physicians are s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye